Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 364

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 364
---
 the contrary, any payment required to be made in respect of the CVRs on such date need not be made on such date, but may be made on the next succeeding Business Day with the same
force and effect as if made on the CVR Payment Date.

[Remainder of Page Left Blank Intentionally]

A-105

IN WITNESS WHEREOF, each of the parties has caused this Agreement to be executed on its behalf by its duly authorized officers as of the day and year first above written.

| XENOTHERAPEUTICS, INC. |
| By                     |
| Name                   |
| Title                  |

A-106

IN WITNESS WHEREOF, each of the parties has caused this Agreement to be executed on its behalf by its duly authorized officers as of the day and year first above written.

| [RIGHTS AGENT] solely in its capacity as Rights Agent |
| By                                                    |
| Name                                                  |
| Title                                                 |

A-107

IN WITNESS WHEREOF, each of the parties has caused this Agreement to be executed on its behalf by its duly authorized officers as of the day and year first above written.

| [REPRESENTATIVE], solely in its capacity as Representative |
| By                                                         |
| Name                                                       |
| Title                                                      |

A-108

ANNEX B FAIRNESS OPINION November 14, 2025 The Board of Directors Repare Therapeutics Inc. 7171 Frederick-Banting, Building 2, Suite 270 St-Laurent, Quebec, Canada H4S 1Z9 Ladies and Gentlemen: You have requested our opinion as to the fairness, from a financial point of view, to the holders of the outstanding common shares, without par value (the “Common Shares”) of Repare Therapeutics Inc., a company existing under the laws of the Province of Quebec (the “Company”), of the Cash Consideration (as defined below) proposed to be paid to such holders pursuant to the terms of the arrangement contemplated by the Arrangement Agreement (the “Agreement”) to be entered into between XenoTherapeutics, Inc., a company existing under the laws of Massachusetts (“Parent”), Xeno Acquisition Corp., a company existing under the laws of Delaware and a wholly-owned subsidiary of Parent (the “Purchaser”), and the Company and, solely for purposes of guaranteeing the obligations of Parent and the Purchaser, XOMA Royalty Corporation, a company existing under the laws of Nevada (“Guarantor”). The Agreement provides